Association between liver fibrosis and appendicular skeletal muscle mass during antiviral therapy in chronic hepatitis B
- 5 August 2020
- journal article
- research article
- Published by Elsevier BV in Digestive and Liver Disease
- Vol. 52 (11), 1338-1345
- https://doi.org/10.1016/j.dld.2020.07.004
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Science, ICT and Future Planning (2019R1A2C4070136)
- National Research Foundation of Korea (2019R1A2C4070136)
This publication has 23 references indexed in Scilit:
- Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise trainingJournal of Cachexia, Sarcopenia and Muscle, 2015
- Change in skeletal muscle mass after administering entecavir in patients with hepatitis BNutrition, 2015
- The FNIH Sarcopenia Project: Rationale, Study Description, Conference Recommendations, and Final EstimatesThe Journals of Gerontology, Series A: Biological Sciences and Medical Sciences, 2014
- How good is controlled attenuation parameter and fatty liver index for assessing liver steatosis in general population: correlation with ultrasoundLiver International, 2013
- Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean populationLiver International, 2013
- Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up studyThe Lancet, 2013
- Clinical applications of transient elastographyClinical and Molecular Hepatology, 2012
- Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis BJournal of Hepatology, 2010
- Variability in liver stiffness values from different intercostal spacesLiver International, 2009
- From Hepatitis to Hepatoma: Lessons from Type B Viral HepatitisScience, 1993